UTMD Q2 Revenue Drops 14% on Lost Customers; Full-Year Guidance Cut to 10-13% Decline
UTMD sits 22% above its 52-week low of $53.66 on elevated volume (4.6× avg).
Summary
UTMD's Q2 revenue fell 14% to $8.53M as lost customers hit hard; full-year guidance slashed to a 10-13% decline. New product sales are lagging, and litigation costs are up. Strong cash position provides a buffer.
Key Events · Earnings and Guidance · UTMD
-
Q2 Revenue Miss
Revenue of $8.53M, down 14.3% YoY, driven by $1.07M loss from two former largest customers.
-
Full-Year Guidance Cut
Management now projects 2026 sales decline of 10-13%, versus prior expectation of flat revenues, as new biopharma OEM sales ramp slower than expected.
-
Litigation Costs Rising
2026 litigation expenses now expected to be less than $1.6M, up from prior estimate of below 2025's $1.355M, due to higher expert witness and motion costs.
-
Strong Balance Sheet
Cash and investments of $87.5M, no debt, and minimal share repurchases of $206K in 1H 2026 provide financial stability.
Analysis · UTMD · Industrial Applications And Services
Utah Medical Products reported Q2 2026 revenue of $8.53 million, down 14.3% year-over-year, driven by the loss of its two largest customers which accounted for $1.07 million of the decline. New biopharma OEM sales, intended to offset these losses, reached only $211,000 in the first half—far slower than planned. Management now expects full-year 2026 sales to decline 10-13%, a sharp reversal from prior guidance of flat revenues. Litigation costs are also running higher than expected, now projected at less than $1.6 million for the year versus the prior estimate of below 2025's $1.355 million. The company maintains a fortress balance sheet with $87.5 million in cash and no debt, and share repurchases were minimal at $206,000 in the first half. The revenue miss and guidance cut signal deeper-than-expected customer concentration risk and a slower new product ramp, raising questions about the growth trajectory.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UTMD was trading at $65.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $209M. The 52-week trading range was $53.66 to $75.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.